Royalty Pharma

62 articles with Royalty Pharma

• MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

  6/2/2021

  MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.

• 

  MorphoSys’ Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma

  6/2/2021

  MorphoSys is acquiring Constellation Pharmaceuticals for about $1.7 billion. It is a stock deal at $34 per share in cash. Morphosys also announced a partnership with Royalty Pharma, with Royalty paying MorphoSys $1.425 billion up front.

• MSCI Announces Strategic Alliance With Royalty Pharma to Launch Life Sciences Indexes

  4/21/2021

  MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced today its collaboration with Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, to expand MSCI’s thematic index suite with the launch of new indexes

• Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million

  4/8/2021

  – Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments

• 

  Biopharma Update on the Novel Coronavirus: December 22

  12/22/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.

• New Ventures Funds Rebrands as Scientia Ventures

  10/2/2020

  New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com.

• Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million

  8/7/2020

  - Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments - Royalty Pharma will purchase new Commercial Launch Preferred Equity from Biohaven for a total of $200 million payable between 2021 and 2024, providing additional funding for its CGRP-targeting franchise

• New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut

  6/25/2020

  New Ventures Funds , a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (NASDAQ:RPRX). The company raised $2.18 billion through the sale of 77,681,670 of its Class A ordinary shares priced at $28.00 per share

• Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty

  6/12/2020

  Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments

• 

  Royalty Pharma Targeting $1.96 Billion IPO

  6/9/2020

  In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share, which would result in raising up to $1.96 billion for its initial public offering.

• Royalty Pharma Acquires Royalties on Entyvio® from Massachusetts General Hospital

  3/5/2020

  Royalty Pharma announced that it has acquired Massachusetts General Hospital's royalty interest in Entyvio for $94 million.

• Christopher Hite Joins Royalty Pharma

  2/28/2020

  Royalty Pharma announced today that Chris Hite has agreed to join the Company as Executive Vice President and Vice Chairman.

• Royalty Pharma Announces Appointment of George Grofik as SVP, Head of Investor Relations and Communications

  1/31/2020

  Royalty Pharma, the largest acquiror of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, announced today that George Grofik has been appointed Senior Vice President, Head of Investor Relations and Communications.

• Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme

  11/5/2019

  Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s (Nasdaq: EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock.

• Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement

  11/4/2019

  Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced funding agreements with Royalty Pharma and its affiliate Pharmakon Advisors that, in aggregate, could bring in up to $270 million in capital, significantly strengthening Epizyme’s financial position and extending its operating runway into at least 2022.

• Royalty Pharma Announces Promotions in Finance Team in Anticipation of Next Growth Phase

  12/3/2018

  - Royalty Pharma is pleased to announce that Susannah Gray has been named Executive Vice President – Finance & Strategy, Terrance Coyne has been promoted to Chief Financial Officer, and Kristin Stafford has been promoted to Chief Accounting Officer.

• 

  Zealand Abandons Sanofi Diabetes Drug in $205 Million Deal with Royalty Pharma

  9/7/2018

  Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.

• Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million

  6/19/2018

  Royalty Pharma acquires approximately 2% royalty rights on global annual net sales of rimegepant and BHV-3500 from Biohaven for $100 million

• Cytokinetics Grabs a $100 Million Deal for Heart Drug With Royalty Pharma

  2/2/2017

• UCLA Sells Royalty Rights Connected with Cancer Drug to Royalty Pharma for $1.14 Billion

  3/7/2016